COX6B1 and hepatocellular carcinoma: Interestingly, miR-224, predicted to target the Ubiquinone Oxidoreductase Subunit A8 and the Cytochrome c oxidase subunit 6B1, has been reported as an early-stage biomarker in HCC patients (64) and as an accelerator of HCC progression (65).